⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29960587 | 1.00 | — | — | |
| Formaldehyde SCHEMBL29230974 | 0.93 | NAPRT (0.45) | — | |
| Formic Acid SCHEMBL28564246 | 0.87 | NAPRT (0.46) | — | |
| Acetic Acid SCHEMBL29148560 | 0.85 | NAPRT (0.53) | — | |
| SCHEMBL30912197 | 0.80 | ALDH1A1 (0.41) | — | |
| SCHEMBL30912198 | 0.78 | CDC25B (0.44) | — | |
| SCHEMBL31095224 | 0.75 | HSD11B1 (0.43) | — | |
| SCHEMBL31095207 | 0.75 | HSD11B1 (0.43) | — | |
| SCHEMBL23349968 | 0.74 | KDM4E (0.39) | — | |
| SCHEMBL255507 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 666 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109265352-B | Preparation method of aryl cyclopropyl ether and derivatives thereof | 杭州迈世腾药物科技有限公司 | 2021-06-04 | — | — | CN | claimed |
| CN-122094678-A | AP 2-related kinase 1 inhibitors and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| WO-2026107328-A1 | AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS | SEPTERNA, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260115199-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4727647-A1 | GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOF | The Broad Institute Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260103465-A1 | GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2026-04-16 | — | — | US | disclosed |
| US-12600728-B2 | Interleukin-17 inhibitors | NOVARTIS AG (CH) | 2026-04-14 | — | — | US | disclosed |
| US-20260098026-A1 | M4 ACTIVATORS/MODULATORS AND USES THEREOF | CEREVEL THERAPEUTICS LLC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12570632-B2 | Indole derivatives and uses thereof for treating a cancer | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2026-03-10 | — | — | US | disclosed |
| WO-2026041636-A1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2026-02-26 | — | — | WO | disclosed |
| EP-1648893-A1 | NICOTINE ADDICTION REDUCING HETEROARYL FUSED AZAPOLYCYCLIC COMPOUNDS | Pfizer Products Inc. (US) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005060949-A2 | SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF HOT FLASHES, IMPULSE CONTROL DISORDERS AND PERSONALITY CHANGE DUE TO A GENERAL MEDICAL CONDITION | ELI LILLY AND COMPANY (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005053663-A2 | NOREPINEPHRINE REUPTAKE INHIBITORS USEFUL FOR TREATMENT OF COGNITIVE FAILURE | ELI LILLY AND COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
| WO-2005023802-A1 | PYRIDINYLMORPHOLINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005020976-A2 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005021095-A2 | TREATMENT OF STUTTERING AND OTHER COMMUNICATION DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005020975-A2 | TREATMENT OF LEARNING DISABILITIES AND MOTOR SKILLS DISORDER WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005007655-A1 | NICOTINE ADDICTION REDUCING HETEROARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20050020830-A1 | Heteroaryl fused azapolycyclic compounds which bind to neuronal nicotinic acetylcholine specific receptor sites, and which are useful in modulating cholinergic function, for for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, therapy | PFIZER INC | 2005-01-27 | — | — | US | disclosed |
| US-3818016-A | HALOGENATED PYRIDINE DERIVATIVES | ICI LTD | 1974-06-18 | — | — | US | disclosed |